DuPont Merck and Mitotix enter $55 mil. cell division regulator cancer collaboration.
Executive Summary
DUPONT MERCK/MITOTIX $55 MIL. CANCER COLLABORATION: CELL DIVISION ENZYMES known as cyclin-dependent kinases will be the focus of the agreement announced jointly by the companies Dec. 7. The collaboration, the first for privately-held Mitotix, initially will focus on identifying inhibitors of cyclin D1 and cyclin E and mimetics of the tumor suppressor gene p16.